<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354545</url>
  </required_header>
  <id_info>
    <org_study_id>19-000843</org_study_id>
    <nct_id>NCT04354545</nct_id>
  </id_info>
  <brief_title>Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications</brief_title>
  <official_title>Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for
      ocular surface discomfort, which will be prescribed as standard of care treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic
      solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma
      antihypertensive medications.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 12 in corneal fluorescein staining score</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Change in corneal fluorescein staining score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to week 12 in eye dryness score (EDS)</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Change in eye dryness score (EDS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire score</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Change in ocular surface disease index (OSDI) questionnaire score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change at intermediate week visits in corneal fluorescein staining score</measure>
    <time_frame>From baseline and at weeks 2, 6, and 12</time_frame>
    <description>Change in corneal fluorescein staining score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change at intermediate week visits in eye dryness score (EDS)</measure>
    <time_frame>From baseline and at weeks 2, 6, and 12</time_frame>
    <description>Change in eye dryness score (EDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change at intermediate week visits in ocular surface disease index (OSDI) questionnaire score</measure>
    <time_frame>From baseline and at weeks 2, 6, and 12</time_frame>
    <description>Change in ocular surface disease index (OSDI) questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the subcategories of ocular surface disease index (OSDI) questionnaire score at intermediate week visits</measure>
    <time_frame>From baseline and at weeks 2, 6, and 12</time_frame>
    <description>Change in subcategory scores of ocular surface disease index (OSDI) questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiidra (Lifitegrast ophthalmic solution) 5%</intervention_name>
    <description>FDA approved lifitegrast opthalmic solution eye drop</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Lifitegrast ophthalmic solution</other_name>
    <other_name>SAR-1118</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Glaucoma patients suffering from ocular surface discomfort
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently using one or more topical glaucoma antihypertensives

          -  Self-described symptoms of ocular surface discomfort

          -  Xiidra is being prescribed as part of the subject's standard care

        Exclusion Criteria:

          -  History of glaucoma filtration surgery, history of ocular surface surgery (pterygium,
             conjunctivoplasty, etc.),

          -  current use of topical cyclosporine

          -  current use of topical steroids

          -  incisional ocular surgery within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin B Bert, MD</last_name>
    <phone>626-817-4701</phone>
    <email>BBert@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin K Garcia, BA</last_name>
    <phone>626-817-4722</phone>
    <email>mkgarcia@mednet.ucla.edu</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Benjamin B. Bert, MD</investigator_full_name>
    <investigator_title>Health Sciences Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>xiidraâ„¢</keyword>
  <keyword>ocular surface discomfort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lifitegrast</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04354545/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

